These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33858996)

  • 1. In Vivo Detection of Underlying Synucleinopathies: Are We There Yet?
    Irwin D; Saint-Hilaire M
    Neurology; 2021 May; 96(20):925-926. PubMed ID: 33858996
    [No Abstract]   [Full Text] [Related]  

  • 2. On the Track of α-Synuclein in the Body: Skin Biopsies for Diagnosing Synucleinopathies?
    Parnetti L; Bellomo G
    Neurology; 2023 Apr; 100(15):691-692. PubMed ID: 36657990
    [No Abstract]   [Full Text] [Related]  

  • 3. Skin nerve α-synuclein deposits in Parkinson's disease and other synucleinopathies: a review.
    Donadio V
    Clin Auton Res; 2019 Dec; 29(6):577-585. PubMed ID: 30506233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving forward the in vivo diagnosis of the synucleinopathies.
    Vilas D
    Clin Auton Res; 2019 Dec; 29(6):575-576. PubMed ID: 30721384
    [No Abstract]   [Full Text] [Related]  

  • 5. Identifying the best biomarkers for α-synucleinopathies.
    Dauvilliers Y
    Lancet Neurol; 2021 Aug; 20(8):593-594. PubMed ID: 34302778
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Longitudinal Skin Biopsy Study of Phosphorylated Alpha-Synuclein in a Patient With Parkinson Disease and Orthostatic Hypotension.
    Infante R; Scaglione C; Incensi A; Rizzo G; Liguori R; Donadio V
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):813-816. PubMed ID: 32529258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin α-synuclein differentiates synucleinopathies.
    Lemprière S
    Nat Rev Neurol; 2023 Mar; 19(3):129. PubMed ID: 36750670
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibodies against alpha-synuclein: tools and therapies.
    Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
    J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD.
    Liguori C; Paoletti FP; Placidi F; Ruffini R; Sancesario GM; Eusebi P; Mercuri NB; Parnetti L
    Curr Neurol Neurosci Rep; 2019 Jan; 19(2):3. PubMed ID: 30637520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARSA variants in α-synucleinopathies.
    Makarious MB; Diez-Fairen M; Krohn L; Blauwendraat C; Bandres-Ciga S; Ding J; Pihlstrøm L; Houlden H; Scholz SW; Gan-Or Z
    Brain; 2019 Dec; 142(12):e70. PubMed ID: 31670782
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic approaches in Parkinson's disease and related disorders.
    Valera E; Masliah E
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):346-352. PubMed ID: 26749150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The novel mechanism of α-synuclein propagation in synucleinopathy].
    Kawahata I
    Nihon Yakurigaku Zasshi; 2021; 156(4):251. PubMed ID: 34193707
    [No Abstract]   [Full Text] [Related]  

  • 16. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts.
    Strohäker T; Jung BC; Liou SH; Fernandez CO; Riedel D; Becker S; Halliday GM; Bennati M; Kim WS; Lee SJ; Zweckstetter M
    Nat Commun; 2019 Dec; 10(1):5535. PubMed ID: 31797870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease and other alpha-synucleinopathies.
    Goedert M
    Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Passive Immunotherapies for Synucleinopathies.
    Bergström AL; Kallunki P; Fog K
    Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.